Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
OBJECTIVE:To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). METHODS:From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retrospectively analyzed. Of these patients, 117 patients...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4352046?pdf=render |
id |
doaj-23555ebdd8ec430392b2f520fac203bb |
---|---|
record_format |
Article |
spelling |
doaj-23555ebdd8ec430392b2f520fac203bb2020-11-25T01:25:09ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011910110.1371/journal.pone.0119101Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.Cai-neng CaoJing-wei LuoLi GaoJun-lin YiXiao-dong HuangKai WangShi-ping ZhangYuan QuSu-yan LiJian-ping XiaoZhong ZhangGuo-zhen XuOBJECTIVE:To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). METHODS:From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retrospectively analyzed. Of these patients, 117 patients were treated by concurrent chemoradiotherapy (CCRT) using IMRT and 63 cases were treated by IMRT alone. RESULTS:The median follow-up time was 58.97 months (range, 2.79-114.92) months. For all the patients, the 1, 3 and 5-year local failure-free survival (LFFS) rates were 97.7%, 89.2% and 85.9%, regional failure free survival (RFFS) rates were 98.9%, 94.4% and 94.4%, distant failure-free survival (DFFS) rates were 89.7%, 79.9% and 76.2%, and overall survival (OS) rates were 92.7%, 78.9% and 65.3%, respectively. No statistically significant difference was observed in LFFS, RFFS, DFFS and OS between the CCRT group and the IMRT alone group. No statistically significant difference was observed in acute toxicity except leukopenia (p = 0.000) during IMRT between the CCRT group and the IMRT alone group. CONCLUSION:IMRT alone for T4 classification NPC achieved similar treatment outcomes in terms of disease local control and overall survival as compared to concurrent chemotherapy plus IMRT. However, this is a retrospective study with a limited number of patients, such results need further investigation in a prospective randomized clinical trial.http://europepmc.org/articles/PMC4352046?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Cai-neng Cao Jing-wei Luo Li Gao Jun-lin Yi Xiao-dong Huang Kai Wang Shi-ping Zhang Yuan Qu Su-yan Li Jian-ping Xiao Zhong Zhang Guo-zhen Xu |
spellingShingle |
Cai-neng Cao Jing-wei Luo Li Gao Jun-lin Yi Xiao-dong Huang Kai Wang Shi-ping Zhang Yuan Qu Su-yan Li Jian-ping Xiao Zhong Zhang Guo-zhen Xu Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. PLoS ONE |
author_facet |
Cai-neng Cao Jing-wei Luo Li Gao Jun-lin Yi Xiao-dong Huang Kai Wang Shi-ping Zhang Yuan Qu Su-yan Li Jian-ping Xiao Zhong Zhang Guo-zhen Xu |
author_sort |
Cai-neng Cao |
title |
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
title_short |
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
title_full |
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
title_fullStr |
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
title_full_unstemmed |
Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
title_sort |
concurrent chemotherapy for t4 classification nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
OBJECTIVE:To evaluate concurrent chemotherapy for T4 classification nasopharyngeal carcinoma (NPC) treated by intensity-modulated radiotherapy (IMRT). METHODS:From July 2004 to June 2011, 180 non-metastatic T4 classification NPC patients were retrospectively analyzed. Of these patients, 117 patients were treated by concurrent chemoradiotherapy (CCRT) using IMRT and 63 cases were treated by IMRT alone. RESULTS:The median follow-up time was 58.97 months (range, 2.79-114.92) months. For all the patients, the 1, 3 and 5-year local failure-free survival (LFFS) rates were 97.7%, 89.2% and 85.9%, regional failure free survival (RFFS) rates were 98.9%, 94.4% and 94.4%, distant failure-free survival (DFFS) rates were 89.7%, 79.9% and 76.2%, and overall survival (OS) rates were 92.7%, 78.9% and 65.3%, respectively. No statistically significant difference was observed in LFFS, RFFS, DFFS and OS between the CCRT group and the IMRT alone group. No statistically significant difference was observed in acute toxicity except leukopenia (p = 0.000) during IMRT between the CCRT group and the IMRT alone group. CONCLUSION:IMRT alone for T4 classification NPC achieved similar treatment outcomes in terms of disease local control and overall survival as compared to concurrent chemotherapy plus IMRT. However, this is a retrospective study with a limited number of patients, such results need further investigation in a prospective randomized clinical trial. |
url |
http://europepmc.org/articles/PMC4352046?pdf=render |
work_keys_str_mv |
AT cainengcao concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT jingweiluo concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT ligao concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT junlinyi concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT xiaodonghuang concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT kaiwang concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT shipingzhang concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT yuanqu concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT suyanli concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT jianpingxiao concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT zhongzhang concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy AT guozhenxu concurrentchemotherapyfort4classificationnasopharyngealcarcinomaintheeraofintensitymodulatedradiotherapy |
_version_ |
1725114928054927360 |